A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Inclusion Criteria

• Moderately to severely active Ulcerative Colitis (UC) diagnosed prior to the Screening Visit

• Evidence of UC extending beyond the rectum, as determined by baseline endoscopy

• Has had an inadequate response, loss of response to, or is intolerant to at least 1 of the following treatments for UC: oral aminosalicylates, systemic corticosteroids, immunomodulators, biologic therapy

Exclusion Criteria

• Diagnosis of Crohn's disease or indeterminate colitis

• Has documentation of positive test for toxin producing Clostridium difficile, or polymerase chain reaction examination of the stool

• Apheresis within 2 weeks of randomization

• History of or currently active primary or secondary immunodeficiency, or participants with known genetic disorders as a cause for colitis

• Other protocol-defined inclusion/exclusion criteria apply